like rome tibsovo label wont built
two fda approv belt multipl label expans potenti
horizon believ agio hallmark long-term success stori see
idhifa tibsovo import addit armamentarium acut myeloid
leukemia aml believ drug may face signific headwind
evolv aml competit landscap revis estim
applaud develop mitapivat pyruv kinas defici pkd forese
potenti difficulti commerci drug may deliv signific benefit
patient greatest needthos suffer sever form pkd
view commerci potenti compani lead program fairli reflect
agio current market capit assum coverag perform rate
see tibsovo sale label expans opportun compani
primari valu driver includ updat sale estim aml
well cholangiocarcinoma model top line result phase
claridhi studi expect could support near-term label expans
cholangiocarcinoma project po program
agio execut ambiti develop strategi expand tibsovo label
beyond r/r diseas multipl trial evalu tibsovo combin
frontlin standard-of-car therapi recal tibsovo approv last juli
relapsed/refractori aml follow footstep idhifa
aml market celgen
see combin venetoclax hypomethyl agent
emerg standard care elderli aml patient potenti threat
tibsovo success frontlin set later month phase result
on-going trial evalu tibsovo combin azacitidin could provid
near-term opportun investor benchmark efficaci venetoclax
believ mitapivat excel chanc po becom first
disease-modifi therapi pkd enrol two on-going phase clinic
trial expect complet end base mitapivat mechan
avail clinic data believ drug efficaci would extend
patient suffer sever form diseas
expect catalyst-rich highlight potenti poc mitapivat
beta thalassemia follow pivot result pkd clinic poc
vorasidenib treatment glioma and/or
solid tumor could offer substanti new avenu growth
cash believ agio adequ cash sustain oper
year price histori
biopharmaceut compani engag
identifi develop therapi
cancer rare genet disord
analyst certif import disclosur see disclosur
label expans tibsovo newly-diagnos aml
patient unfit fit standard induct chemotherapi
respect
tibsovo aml sale us eu market
approv tibsovo cholangiocarcinoma
gener peak sale
royalti idhifa sale
approv mitapivat pkd peak sale
believ agio market capit fairli reflect
opportun tibsovo mitapivat addit
expect royalti idhifa sale model includ
contribut tibsovo three indic relapsed/
sale po r/r cholangiocarcinoma
peak sale po model also includ
contribut mitapivat pkd peak sale
po addit expect compani receiv
substanti royalti revenu stream idhifa sale
agreement celgen peak po
claridhi
potenti updat data tibsovo hma combin
potenti present data periop trial vorasidenib
glioma
potenti mitapivat demonstr clinic proof-of-concept
beta thalassemia
potenti tibsovo label expans aml frontlin set
current untreat patient
potenti result dose escal portion on-going
higher-than-expect penetr tibsovo idhifa and/
mitapivat
tibsovo label expans myelodysplast syndrom
regulatori approv success commerci
mitapivat beta thalassemia
success develop commerci vorasidenib
lower-than-anticip market penetr tibsovo
failur tibsovo expand label newli diagnos aml
cholangiocarcinoma indic
reduc market opportun due lower-than-anticip
price tibsovo and/or mitapivat
failur activ and/or activate-t trial achiev
primari endpoint reduc chanc approv mitapivat
commercial-stag biotechnolog compani
headquart cambridg compani core therapeut area includ
cancer metabol metabol immuno-oncolog mio rare genet
diseas agio first product idhifa approv august
treatment adult patient relaps refractori acut myeloid leukemia
aml isocitr mutat
market celgen similarli tibsovo target mutant aml patient
approv juli r/r set wholly-own agio
compani pipelin includ multipl program clinic develop
includ pyruv kinase-r pkr activ mitapivat treatment
pyruv kinas defici pkd cns-permeabl inhibitor
vorasidenib treatment glioma inhibitor
solid tumor develop collabor
celgen joint world-wide collabor agreement fourth pipelin asset
could enter clinic later treatment lymphoma
assum coverag perform rate base assess
commerci potenti compani approv product late clinical-stag
pipelin base convers hematologist believ target
therapi aml tibsovo idhifa undoubtedli play
import role futur treatment paradigm also believ drug
fundament limit rel small fraction address aml
patient harbor mutat model includ revis
sale estim tibsovo opinion reflect increasingli
competit landscap frontlin aml set revenu
revenu project tibsovo cholangiocarcinoma well mitapivat
pkd sum-of-the-part npv exhibit suggest commerci
potenti compani product fairli reflect compani
market capit current ascrib valu compani earli
clinical-stag program includ mitapivat beta thalassemia vorasidenib
howev proof-of-concept data program next
follow tibsovo initi approv monotherapi relapsed/refractori
r/r set agio embark ambiti clinic develop strategi
aim expand drug label confid po
on-going hovon agil phase trial could use support approv
tibsovo multipl frontlin combin includ standard induct
chemotherapi hypomethyl agent hma patient unfit
induct howev believ tibsovo could face stiff competit
venetoclax hma combin recent approv use elderli
aml patient patient comorbid preclud use intens
induct chemotherapi venetoclax combin perform
particularli well idh mutant requir up-front genet test
believ venetoclax hma could becom de facto standard care aml
patient unfit induct high intens chemotherapi
agio pipelin develop effort extend well beyond oncolog
compani current run parallel phase trial transfusion-depend
transfusion-independ pkd activ activate-t despit
high convict po potenti market approv mitapivat
acknowledg potenti difficulti success commerci therapi
orphan indic patient present wide spectrum
symptom sever believ larg segment pkd popul
defin underli genotyp unlik deriv benefit pyruv
kinas stabil mitapivat
agio also investig mitapivat exploratori trial beta thalassemia
could potenti expand therapi much larger indic
howev given lack clear read-through pkr activ beta
thalassemia sever await proof-of-concept data trial
includ indic estim
summar exhibit major valuat center combin
market opportun tibsovo aml per share mitapivat
pkd per share smaller contribut tibsovo
cholangiocarcinoma per share idhifa royalti mileston
payment celgen per share
believ risk adjust larg line histor data
success rate drug base current stage develop natur
review drug discoveri sum-of-the-part valuat
two program summar includ project cash
posit per share npv sum approxim
current ascrib valu agio earlier stage program
repres upsid estim compani explor mitapivat
anoth form chronic anemia beta thalassemia could present earli proof
concept data end molecul develop
oncolog indic includ data gener
earli trial drug could present
oppenheim co inc estim intend price target
invest recommend depend agio abil success
develop manufactur commerci product assess
potenti tibsovo frontlin aml base encourag singl arm
clinic trial result data may hold random control trial
agil hovon failur demonstr statist clinic
signific could result failur gain regulatori approv label expans
separ agio may experi delay advanc pipelin may
realiz full commerci potenti neg affect calcul market
valu compani
agio program may face signific competit could prevent
compani achiev peak sale line estim exampl
fda recent approv abbvi venclexta treatment adult patient
newli diagnos aml venclexta requir up-front
biomark test may neg impact futur market share target therapi
idh biomarker-posit patient
newli commercial-stag biotechnolog compani abil
maintain suffici fund critic develop progress pipelin
candid model includ one equiti financ could
potenti support compani profit agio rais capit
need may forc delay elimin product develop
program commerci effort
pipelin clinic program
potenti updat phase data combin hma isal februari
potenti interim data claridhi trial cholangiocarcinoma
potenti snda approv frontlin treatment treatment-inelig patient
potenti approv relapsed/refractori aml
potenti complet enrol phase agil trial
potenti approv relapsed/refractori aml
potenti proof-of-concept phase data beta thalassemia
potenti compet enrol activ activate-t
potenti phase dose-escal data readout patient w/ mtap-delet tumor
potenti initi phase trial lymphoma
potenti initi vorasidenib phase trial low-grad glioma
compani present oppenheim co estim
overview major program
idhifa tibsovo mitapivat advanc product emerg
agio innov drug develop platform far target metabol
pathway activ drive diseas includ cancer rare genet
disord exampl mutat isocitr dehydrogenas idh enzym
present patient aml mutant idh catalyz product
oncometabolit promot hypermethyl
dna histon promot express cancer-driv oncogen asid
aml idh mutat also found solid tumor
cholangiocarcinoma bile duct cancer glioma lesser extent
mitapivat oral avail small-molecul alloster activ pkr
enzym whose activ diminish rare genet disord pyruv kinas
defici pkd patient pkd suffer life-long anemia typic
manag transfus mitapivat current evalu two parallel
phase trial patient pkd believ trial support strong
evid prior phase trial drive-pk non-transfus depend
pkd demonstr daili dose mitapivat could improv underli
idh inhibitor aml
idhifa tibsovo current approv aml relapsed/refractori
diseas set idhifa approv august specif inhibit
isoform idh enzym estim occur aml
patient tibsovo approv juli inhibit isoform
estim occur aml patient therapi
approv base monotherapi activ seen patient test posit
relev mutat use companion diagnost
idhifa registr trial treat relaps refractori
aml patient mg daili tibsovo registr trial
treat patient mg daili efficaci result
summar tabl
exhibit efficaci idhifa tibsovo monotherapi r/r aml
idhifa tibsovo well toler trial
common advers event includ diarrhea nausea grade
differenti syndrom activ manag steroid
immunosupress incid grade higher differenti syndrom
around
believ success commerci idhifa tibsovo
ultim hing integr frontlin treatment paradigm
market opportun novel drug larger frontlin aml segment
set treatment decis ultim made base underli patient
genet risk factor physician choic two main option includ
intens chemotherapi induct typic reserv physic
fit patient non-intens option unfit patient includ use
agio partner celgen current enrol patient random
hovon trial explor tibsovo idhifa combin intens
chemotherapi second trial agil pit combin tibsovo
hma versu hma alon physic unfit patient
data prior trial explor combin encourag
meet tibsovo
residu diseas mrd evalu patient complet remiss
idhifa elimin mrd patient abstract durabl
respons yet evalu although patient still aliv
one year believ preliminari outcom compar favor
expect intens induct alon clin oncol aug
ascrib po posit top line result hovon
updat result separ phase trial explor tibsovo idhifa
combin hma present june efficacy-
evalu patient tibsovo combin azacitidin demonstr
composit cr rate data avail six patient idhifa
combin three achiev although earli believ data could
foreshadow signific improv benchmark respons
rate hma monotherapi blood jul ascrib
po posit outcom agil
despit larger market opportun frontlin maintain
conserv estim penetr frontlin set due recent
approv venetoclax inhibitor label use combin
hma patient unfit standard induct therapi updat data
two open label trial led fda
approv present meet total composit cr
rate cr cri patient treat azacitidin
combin patient treat decitabin
combin median overal surviv around month
patient achiev respons maintain respons one year
venetoclax hma combin appear particularli potent
mutant composit cr increas
respect discuss hematologist feel
consider excit combin particularli repres
chemotherapy-fre option patient strength data agil
could ultim determin idh inhibitor success set venetoclax
combin like benefit first mover advantag venetoclax
hma efficaci data set rel high bar idh inhibitor clear
tibsovo market opportun
aml common leukemia incid roughli new
case us year per seer statist newli diagnos
mutat occur patient price estim assum list
price per cycl patient continu therapi averag five
broken estim market model frontlin set
relapse/refractori set summar exhibit tibsovo current
approv us treatment r/r patient submit
ema decemb anticip eu approv
believ idh inhibitor benefit sizeabl market opportun
relapsed/refractori set aml treatment frontlin set vari
depend patient genet risk factor estim patient
refractori frontlin therapi relaps achiev
respons frontlin convers physician activ
prescrib idh inhibitor r/r patient suggest genet test idh
mutat may creat signific barrier uptak re-induct
chemotherapi commonli cite potenti competitor idh inhibitor
especi physic fit patient achiev good respons frontlin
induct current model penetr us eu market r/r
set biomarker-posit patient
frontlin therapi aml uniform across field estim
roughli patient receiv standard induct chemotherapi receiv
less intens treatment includ hma patient receiv
palli support agio expect file supplement nda
approv tibsovo frontlin set small segment untreat
patient project us approv eu approv
believ label expans us eu could occur
follow posit data agil hovon trial respect
assum peak market penetr frontlin indic
driven mainli lower penetr hma combin set
exhibit market model tibsovo aml
idhifa market model aml
idhifa market celgen current indic treatment
mutat aml patient relaps refractori frontlin
therapi estim preval mutat idhifa
market celgen world-wide commerci agreement
agio elig receiv tier royalti sale mileston
approv idhifa r/r set
celgen plan expand idhifa label includ treatment frontlin
set model assum similar timelin probabl success
peak market penetr frontlin r/r treatment set
market model exhibit current includ supplementari approv
frontlin untreat set celgen disclos plan
diagnos aml cases/year posit aml cases/year postiv cases/year cost frontlin market size frontlin sale market penetr patient treat r/r market size r/r sale market penetr patient treat adjust adjust sale newli diagnos aml cases/year posit aml cases/year postiv cases/year cost frontlin market size frontlin sale market penetr patient treat r/r market size r/r sale market penetr patient treat adjust adjust sale profit oper expens tax discount aml us eu agio pharmaceut
exhibit market model idhifa aml
cholangiocarcinoma
cholangiocarcinoma rare aggress cancer treatment option
mutat occur case believ tibsovo could benefit
low bar approv indic carcinog agio
current vet drug random claridhi trial
compar tibsovo placebo patient alreadi fail least two
prior therapi preliminari data could avail
full data present estim approv
cholangiocarcinoma could add patient us eu
combin address tibsovo popul assum po
claridhi market model summar exhibit
diagnos aml cases/year posit aml cases/year postiv cases/year cost frontlin market size royalti frontlin sale agio market penetr patient treat r/r market size royalti r/r sale agio market penetr patient treat payment adjust adjust revenu agio risk adjust mileston payment agio diagnos aml cases/year posit aml cases/year postiv cases/year cost frontlin market size royalti frontlin sale agio market penetr patient treat r/r market size royalti r/r sale agio market penetr patient treat payment adjust adjust sale agio adjust mileston agio revenu discount aml us eu perform na
exhibit market model tibsovo cholangiocarcinoma
mitapivat pkd statu report
mitapivat evalu phase trial orphan indic pkd
disord curtail lifespan red blood cell rbc lead chronic
hemolyt anemia patient pkd typic present symptom includ
dizzi short breath fatigu often patient pkd requir
regular transfus manag symptom
pkd caus mutat pkr pyruv kinas enzym found rbc
pkr catalyz critic last step glycolysi ubiquit metabol pathway
use cell convert glucos energi rbc
mitochondria reli glycolysi support energi demand
pkd patient rbc produc less atp intermedi
metabolit without suffici atp store rbc maintain
plasma membran ion gradient ultim die increas hemolysi
hallmark pkd
believ mitapivat potenti becom first disease-modifi
treatment approv pkd drug stabil pkr enzym improv
effici phase drive-pk trial patient
experienc maximum hgb increas g/dl mean maximum
increas g/dl rang g/dl includ patient
non-missens mutat least one two copi enzym note
patient sever non-missens mutat present copi pkr
gene gener show poor hgb respons see exhibit
case bile duct cancer/year posit cases/year cost market size sale penetr treat adjust adjust sale case bile duct cancer/year posit cases/year cost market size sale penetr treat adjust adjust sale profit oper expens tax discount cholangiocarcinoma us eu agio pharmaceut
agio current investig mitapivat potenti two registrational-ori
trial activ activate-t activ trial enrol
approxim patient non-transfus depend pkd primari
endpoint focus proport patient achiev g/dl improv
hemoglobin six-month period activate-t trial expect
enrol patient transfusion-depend pkd reduct
transfus burden measur one year serv primari endpoint
expect trial readout
mitapivat may struggl find patient
although anticip posit readout on-going activ trial
po believ mitapivat may struggl find patient would benefit
therapi pkd extrem rare diseas preval estim
vari wide believ patient us
patient eu pkd blood dec within
popul sever diseas vari significantli base
convers physician believ mani patient pkd despit
increas hemolysi rare experi symptom sever enough
drive seek treatment
believ primari market mitapivat would individu moder
sever diseasethos requir regular semi-regular transfus
similar estim overal preval pkd estim proport
pkd patient moder sever diseas also challeng model
use proport patient receiv splenectomi per blood
may proxi diseas sever splenectomi
proven reduc hemolysi improv anemia standard care
pkd patient diseas symptomatolog
importantli believ data drive-pk studi suggest mitapivat
effect patient retain partial pkr activ patient harbor
missens mutat oppos truncat delet mutat pkr
gene doubl delet enzym residu pkr
mitapivat activ use natur histori studi estim
symptomat pkd patient doubl delet genotyp thu believ
identif patient good candid mitapivat may
model us approv mitapivat eu approv
assum agio charg per year drug us per
year eu estim price line recent approv
therapi ultra orphan genet disord palynziq
exhibit market model mitapivat pkd
decemb agio cash cash equival
market secur estim could sustain oper
project loss
per share respect agio sever candid earli clinic
program includ vorasidenib glioma solid tumor mitapivat
thalassemia mtap-delet tumor result anticip
heavi expenditur believ agio
turn profit start nich pipelin help creat market
share oncolog rare diseas space
believ tibsovo approv frontlin mutant aml
indic could gener peak non-risk adjust sale
addit forecast tibsovo relapsed/refractori aml peak sale
r/r cholangiocarcinoma peak sale model project
revenu mitapivat pkd peak sale also
incorpor idhifa collaboration/royalti revenu celgen peak
royalti
project respect
 project includ clinic trial expenditur variou set
includ tibsovo phase agil trial aml mitapivat activ
activate-t trial pkd phase trial mtap-delet tumor
vorasidenib phase trial glioma phase trial
lymphoma given potenti fda approv also assign higher sg
expenditur fy respect
compar prior year
pd patient elig mitapivat cost market size sale penetr treat adjust adjust sale pd patient elig mitapivat cost market size sale penetr treat adjust adjust sale profit oper expens tax discount pkd us eu perform na
sec file oppenheim co research
figur thousand except per share revenu net revenu relat revenu revenu relat expens research develop sell gener administr oper loss interest loss incom tax benefit incom loss per share share outstand co mark breidenbach
sec file oppenheim co research
figur thousand except per share cash maret prepaid expens current receiv current properti equip long-term secur current liabil account accru defer revenu current defer rent current total current defer rent net current defer revenu net current prefer stockcommon addit paid-in accumul comprehens accumul stockhold liabil stockhold co mark breidenbach perform na
price compani mention report
